PD-1 Antibody SHR-1210 Combined With Apatinib of First-line Treatment of Advanced Acral Melanoma

Sponsor
Peking University Cancer Hospital & Institute
Study ID
NCT03955354
Phase
PHASE2
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • SHR1210 — DRUG
    SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody
  • apatinib mesylate — DRUG
    apatinib Mesylate is a small molecule tyrosine kinase inhibitor,Through selectively inhibiting the tyrosine kinase activity of the vascular endothelial growth factor receptor 2 (VEGFR-2).

Study Details

the investigators launched this exploratory study to evaluate the objective response rate (ORR) of SHR-1210 combined with apatinib mesylate in the first-line treatment of patients with advanced acral melanoma.

Key Dates

Start date
Mar 5, 2019
Status verified
May 2019
Primary completion
Apr 10, 2020
Completion
Apr 10, 2021

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: experimental arm
    SHR1210 plus apatinib

Primary Outcome Measure

ORR [ Time Frame: Time Frame: Through study completion, an average of 1 year ]

Related Studies